Interleukin-3 - Novartis
Alternative Names: Hemokine; ILE 964; Interleukin-3 - Sandoz; Muplestim; SDZ ILE 964Latest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Wyeth
- Class Antineoplastics; Interleukins
- Mechanism of Action Interleukin 3 stimulants; Stem cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hodgkin's disease; Myeloid leukaemia; Non-Hodgkin's lymphoma; Thrombocytopenia
Most Recent Events
- 12 Sep 2006 Discontinued - Phase-II for Myeloid leukaemia in Netherlands (IV-infusion)
- 12 Sep 2006 Discontinued - Phase-II for Thrombocytopenia in Japan (Infusion)
- 12 Sep 2006 Discontinued - Phase-III for Hodgkin's disease in European Union (IV-infusion)